Study of Ruxolitinib Cream in Children With Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2023-02-22
Target enrollment:
Participant gender:
Summary
This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and
blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in
pediatric participants with atopic dermatitis (AD) and to determine if its systemic
bioavailability results in any adverse events.